HAMP and acquired polycythemia vera: Similarly, in PV, the phase III VERIFY trial (NCT05210790) utilizes MF-SAF v4.0 to assess outcomes in phlebotomy-dependent PV patients receiving standard care, evaluating the hepcidin mimetic peptide therapy Rusfertide against placebo.